172 related articles for article (PubMed ID: 29129052)
1. Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.
Perrey DA; Decker AM; Zhang Y
ACS Chem Neurosci; 2018 Mar; 9(3):587-602. PubMed ID: 29129052
[TBL] [Abstract][Full Text] [Related]
2. Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.
Perrey DA; German NA; Decker AM; Thorn D; Li JX; Gilmour BP; Thomas BF; Harris DL; Runyon SP; Zhang Y
ACS Chem Neurosci; 2015 Apr; 6(4):599-614. PubMed ID: 25643283
[TBL] [Abstract][Full Text] [Related]
3. Orexins modulate the growth of cultured rat adrenocortical cells, acting through type 1 and type 2 receptors coupled to the MAPK p42/p44- and p38-dependent cascades.
Spinazzi R; Ziolkowska A; Neri G; Nowak M; Rebuffat P; Nussdorfer GG; Andreis PG; Malendowicz LK
Int J Mol Med; 2005 May; 15(5):847-52. PubMed ID: 15806308
[TBL] [Abstract][Full Text] [Related]
4. Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement.
Duxon MS; Stretton J; Starr K; Jones DN; Holland V; Riley G; Jerman J; Brough S; Smart D; Johns A; Chan W; Porter RA; Upton N
Psychopharmacology (Berl); 2001 Jan; 153(2):203-9. PubMed ID: 11205420
[TBL] [Abstract][Full Text] [Related]
5. The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.
Perrey DA; Decker AM; Li JX; Gilmour BP; Thomas BF; Harris DL; Runyon SP; Zhang Y
Bioorg Med Chem; 2015 Sep; 23(17):5709-24. PubMed ID: 26216017
[TBL] [Abstract][Full Text] [Related]
6. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.
Perrey DA; German NA; Gilmour BP; Li JX; Harris DL; Thomas BF; Zhang Y
J Med Chem; 2013 Sep; 56(17):6901-16. PubMed ID: 23941044
[TBL] [Abstract][Full Text] [Related]
7. Orexins stimulate glucocorticoid secretion from cultured rat and human adrenocortical cells, exclusively acting via the OX1 receptor.
Ziolkowska A; Spinazzi R; Albertin G; Nowak M; Malendowicz LK; Tortorella C; Nussdorfer GG
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):423-9. PubMed ID: 16157481
[TBL] [Abstract][Full Text] [Related]
8. SB 334867, a selective orexin receptor type 1 antagonist, elevates seizure threshold in mice.
Socała K; Szuster-Ciesielska A; Wlaź P
Life Sci; 2016 Apr; 150():81-8. PubMed ID: 26916826
[TBL] [Abstract][Full Text] [Related]
9. Selective orexin receptor antagonists.
Lebold TP; Bonaventure P; Shireman BT
Bioorg Med Chem Lett; 2013 Sep; 23(17):4761-9. PubMed ID: 23891187
[TBL] [Abstract][Full Text] [Related]
10. Orexin research: patent news from 2016.
Boss C; Roch C
Expert Opin Ther Pat; 2017 Oct; 27(10):1123-1133. PubMed ID: 28631980
[TBL] [Abstract][Full Text] [Related]
11. SB-334867, an orexin receptor 1 antagonist, decreased seizure and anxiety in pentylenetetrazol-kindled rats.
Kordi Jaz E; Moghimi A; Fereidoni M; Asadi S; Shamsizadeh A; Roohbakhsh A
Fundam Clin Pharmacol; 2017 Apr; 31(2):201-207. PubMed ID: 27739093
[TBL] [Abstract][Full Text] [Related]
12. Expression of orexin B and its receptor 2 in rat testis.
Liguori G; Pavone LM; Assisi L; Langella E; Tafuri S; Mirabella N; Costagliola A; Vittoria A
Gen Comp Endocrinol; 2017 Feb; 242():66-73. PubMed ID: 26631456
[TBL] [Abstract][Full Text] [Related]
13. Orexin A and B in vitro modify orexins receptors expression and gonadotropins secretion of anterior pituitary cells of proestrous rats.
Cataldi NI; Lux Lantos VA; Libertun C
Regul Pept; 2014 Jan; 188():25-30. PubMed ID: 24333629
[TBL] [Abstract][Full Text] [Related]
14. Impact of proestrous milieu on expression of orexin receptors and prepro-orexin in rat hypothalamus and hypophysis: actions of Cetrorelix and Nembutal.
Silveyra P; Catalano PN; Lux-Lantos V; Libertun C
Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E820-8. PubMed ID: 17122088
[TBL] [Abstract][Full Text] [Related]
15. Study of human Orexin-1 and -2 G-protein-coupled receptors with novel and published antagonists by modeling, molecular dynamics simulations, and site-directed mutagenesis.
Heifetz A; Morris GB; Biggin PC; Barker O; Fryatt T; Bentley J; Hallett D; Manikowski D; Pal S; Reifegerste R; Slack M; Law R
Biochemistry; 2012 Apr; 51(15):3178-97. PubMed ID: 22448975
[TBL] [Abstract][Full Text] [Related]
16. The Subthalamic Neurons are Activated by Both Orexin-A and Orexin-B.
Sheng Q; Xue Y; Wang Y; Chen AQ; Liu C; Liu YH; Chu HY; Chen L
Neuroscience; 2018 Jan; 369():97-108. PubMed ID: 29138106
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials.
Williams JT; Bolli MH; Brotschi C; Sifferlen T; Steiner MA; Treiber A; Gatfield J; Boss C
J Med Chem; 2024 Feb; 67(4):2337-2348. PubMed ID: 38331429
[TBL] [Abstract][Full Text] [Related]
18. Orexins/hypocretins modulate the activity of NPY-positive and -negative neurons in the rat intergeniculate leaflet via OX1 and OX2 receptors.
Palus K; Chrobok L; Lewandowski MH
Neuroscience; 2015 Aug; 300():370-80. PubMed ID: 26022361
[TBL] [Abstract][Full Text] [Related]
19. Preproorexin and orexin receptors are expressed in cortisol-secreting adrenocortical adenomas, and orexins stimulate in vitro cortisol secretion and growth of tumor cells.
Spinazzi R; Rucinski M; Neri G; Malendowicz LK; Nussdorfer GG
J Clin Endocrinol Metab; 2005 Jun; 90(6):3544-9. PubMed ID: 15797953
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26.
Rinne MK; Leino TO; Turku A; Turunen PM; Steynen Y; Xhaard H; Wallén EAA; Kukkonen JP
Eur J Pharmacol; 2018 Oct; 837():137-144. PubMed ID: 30194937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
